Battalion Oil (BATL)
(Delayed Data from AMEX)
$6.65 USD
-0.02 (-0.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.62 -0.03 (-0.45%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BATL 6.65 -0.02(-0.30%)
Will BATL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BATL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BATL
Battalion Oil (BATL) Earnings & Revenues Decline Y/Y in Q2
Zacks Initiates Coverage of Battalion Oil With Underperform Recommendation
BATL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Battalion Oil Corporation (BATL) Reports Q2 Loss, Tops Revenue Estimates
New Strong Sell Stocks for August 14th
Talos Energy (TALO) Lags Q2 Earnings and Revenue Estimates
Other News for BATL
Battalion Oil: The Acquisition Attempt By Fury Resources May Finally Go Through
Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more
What You Missed On Wall Street On Friday
FedEx reports downbeat Q1, Nike vet returns as new CEO: Morning Buzz
Morning Movers: Apellis slips following negative CHMP opinion